Cancer Vaccine Institute News

DNA-based HER2 vaccine has stronger anti-cancer immune response compared to HER2 peptide vaccines

Dr. Ying Liu presented this study at the 2025 San Antonio Breast Cancer Symposium At the UW Cancer Vaccine Institute, we are working to develop vaccines that train the immune system to recognize and eliminate cancer. At the 2025 San Antonio Breast Cancer Symposium, we shared new data comparing two of our HER2-targeted therapeutic vaccine platforms for people with advanced HER2-positive breast cancer. About 20% of all breast cancers overexpress the HER2 protein, which can make

Sarah White

Feb 17

CVI's WOKVAC, a HER2-directed vaccine, shows promising results in multicenter clinical trial

The Cancer Vaccine Institute (CVI) was excited to share new results from a multi-center clinical trial led by Moffitt Cancer Center at the 2025 San Antonio Breast Cancer Symposium. These results offer encouraging evidence for WOKVAC, a HER2-targeted DNA vaccine developed here at the CVI. In this study, Moffitt and collaborating sites evaluated whether HER2 vaccination could help prevent recurrence in patients at especially high risk, including individuals who still have invas

Sarah White

Feb 17